130 related articles for article (PubMed ID: 32358915)
1. Targeting the Water Network in Cyclin G-Associated Kinase (GAK) with 4-Anilino-quin(az)oline Inhibitors.
Asquith CRM; Tizzard GJ; Bennett JM; Wells CI; Elkins JM; Willson TM; Poso A; Laitinen T
ChemMedChem; 2020 Jul; 15(13):1200-1215. PubMed ID: 32358915
[TBL] [Abstract][Full Text] [Related]
2. Design and Analysis of the 4-Anilinoquin(az)oline Kinase Inhibition Profiles of GAK/SLK/STK10 Using Quantitative Structure-Activity Relationships.
Asquith CRM; Laitinen T; Bennett JM; Wells CI; Elkins JM; Zuercher WJ; Tizzard GJ; Poso A
ChemMedChem; 2020 Jan; 15(1):26-49. PubMed ID: 31675459
[TBL] [Abstract][Full Text] [Related]
3. Identification and Optimization of 4-Anilinoquinolines as Inhibitors of Cyclin G Associated Kinase.
Asquith CRM; Laitinen T; Bennett JM; Godoi PH; East MP; Tizzard GJ; Graves LM; Johnson GL; Dornsife RE; Wells CI; Elkins JM; Willson TM; Zuercher WJ
ChemMedChem; 2018 Jan; 13(1):48-66. PubMed ID: 29072804
[TBL] [Abstract][Full Text] [Related]
4. Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
Asquith CRM; Naegeli KM; East MP; Laitinen T; Havener TM; Wells CI; Johnson GL; Drewry DH; Zuercher WJ; Morris DC
J Med Chem; 2019 May; 62(9):4772-4778. PubMed ID: 30973735
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 3-phenyl- and 3-N-piperidinyl-isothiazolo[4,3-b]pyridines as highly potent inhibitors of cyclin G-associated kinase.
Martinez-Gualda B; Saul S; Froeyen M; Schols D; Herdewijn P; Einav S; De Jonghe S
Eur J Med Chem; 2021 Mar; 213():113158. PubMed ID: 33497888
[TBL] [Abstract][Full Text] [Related]
6. Selective Inhibitors of Cyclin G Associated Kinase (GAK) as Anti-Hepatitis C Agents.
Kovackova S; Chang L; Bekerman E; Neveu G; Barouch-Bentov R; Chaikuad A; Heroven C; Šála M; De Jonghe S; Knapp S; Einav S; Herdewijn P
J Med Chem; 2015 Apr; 58(8):3393-410. PubMed ID: 25822739
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationship study of the pyridine moiety of isothiazolo[4,3-b]pyridines as antiviral agents targeting cyclin G-associated kinase.
Martinez-Gualda B; Pu SY; Froeyen M; Herdewijn P; Einav S; De Jonghe S
Bioorg Med Chem; 2020 Jan; 28(1):115188. PubMed ID: 31757682
[TBL] [Abstract][Full Text] [Related]
8. Targeting an EGFR Water Network with 4-Anilinoquin(az)oline Inhibitors for Chordoma.
Asquith CRM; Maffuid KA; Laitinen T; Torrice CD; Tizzard GJ; Crona DJ; Zuercher WJ
ChemMedChem; 2019 Oct; 14(19):1693-1700. PubMed ID: 31424613
[TBL] [Abstract][Full Text] [Related]
9. Gefitinib and luteolin cause growth arrest of human prostate cancer PC-3 cells via inhibition of cyclin G-associated kinase and induction of miR-630.
Sakurai MA; Ozaki Y; Okuzaki D; Naito Y; Sasakura T; Okamoto A; Tabara H; Inoue T; Hagiyama M; Ito A; Yabuta N; Nojima H
PLoS One; 2014; 9(6):e100124. PubMed ID: 24971999
[TBL] [Abstract][Full Text] [Related]
10. Optimization of Isothiazolo[4,3- b]pyridine-Based Inhibitors of Cyclin G Associated Kinase (GAK) with Broad-Spectrum Antiviral Activity.
Pu SY; Wouters R; Schor S; Rozenski J; Barouch-Bentov R; Prugar LI; O'Brien CM; Brannan JM; Dye JM; Herdewijn P; De Jonghe S; Einav S
J Med Chem; 2018 Jul; 61(14):6178-6192. PubMed ID: 29953812
[TBL] [Abstract][Full Text] [Related]
11. Discovery of pyrido[3,4-g]quinazoline derivatives as CMGC family protein kinase inhibitors: Design, synthesis, inhibitory potency and X-ray co-crystal structure.
Esvan YJ; Zeinyeh W; Boibessot T; Nauton L; Théry V; Knapp S; Chaikuad A; Loaëc N; Meijer L; Anizon F; Giraud F; Moreau P
Eur J Med Chem; 2016 Aug; 118():170-7. PubMed ID: 27128181
[TBL] [Abstract][Full Text] [Related]
12. SGC-GAK-1: A Chemical Probe for Cyclin G Associated Kinase (GAK).
Asquith CRM; Berger BT; Wan J; Bennett JM; Capuzzi SJ; Crona DJ; Drewry DH; East MP; Elkins JM; Fedorov O; Godoi PH; Hunter DM; Knapp S; Müller S; Torrice CD; Wells CI; Earp HS; Willson TM; Zuercher WJ
J Med Chem; 2019 Mar; 62(5):2830-2836. PubMed ID: 30768268
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, biological evaluation and molecular modelling studies of 4-anilinoquinazoline derivatives as protein kinase inhibitors.
Waiker DK; Karthikeyan C; Poongavanam V; Kongsted J; Lozach O; Meijer L; Trivedi P
Bioorg Med Chem; 2014 Mar; 22(6):1909-15. PubMed ID: 24530227
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk).
Mott BT; Tanega C; Shen M; Maloney DJ; Shinn P; Leister W; Marugan JJ; Inglese J; Austin CP; Misteli T; Auld DS; Thomas CJ
Bioorg Med Chem Lett; 2009 Dec; 19(23):6700-5. PubMed ID: 19837585
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and characterization of "clickable" 4-anilinoquinazoline kinase inhibitors.
Perera BG; Maly DJ
Mol Biosyst; 2008 Jun; 4(6):542-50. PubMed ID: 18493651
[TBL] [Abstract][Full Text] [Related]
16. Structure-based lead identification of ATP-competitive MK2 inhibitors.
Barf T; Kaptein A; de Wilde S; van der Heijden R; van Someren R; Demont D; Schultz-Fademrecht C; Versteegh J; van Zeeland M; Seegers N; Kazemier B; van de Kar B; van Hoek M; de Roos J; Klop H; Smeets R; Hofstra C; Hornberg J; Oubrie A
Bioorg Med Chem Lett; 2011 Jun; 21(12):3818-22. PubMed ID: 21565500
[TBL] [Abstract][Full Text] [Related]
17. Theoretical analysis of the binding of potential inhibitors to protein kinases MK2 and MK3.
Araújo PM; da Silva LP; Esteves da Silva JC
Med Chem; 2015; 11(6):573-9. PubMed ID: 25665652
[TBL] [Abstract][Full Text] [Related]
18. Fragment-based identification and optimization of a class of potent pyrrolo[2,1-f][1,2,4]triazine MAP4K4 inhibitors.
Wang L; Stanley M; Boggs JW; Crawford TD; Bravo BJ; Giannetti AM; Harris SF; Magnuson SR; Nonomiya J; Schmidt S; Wu P; Ye W; Gould SE; Murray LJ; Ndubaku CO; Chen H
Bioorg Med Chem Lett; 2014 Sep; 24(18):4546-4552. PubMed ID: 25139565
[TBL] [Abstract][Full Text] [Related]
19. Potency switch between CHK1 and MK2: discovery of imidazo[1,2-a]pyrazine- and imidazo[1,2-c]pyrimidine-based kinase inhibitors.
Meng Z; Ciavarri JP; McRiner A; Zhao Y; Zhao L; Reddy PA; Zhang X; Fischmann TO; Whitehurst C; Arshad Siddiqui M
Bioorg Med Chem Lett; 2013 May; 23(10):2863-7. PubMed ID: 23587425
[TBL] [Abstract][Full Text] [Related]
20. 2,4-Diaminopyrimidine MK2 inhibitors. Part I: Observation of an unexpected inhibitor binding mode.
Argiriadi MA; Ericsson AM; Harris CM; Banach DL; Borhani DW; Calderwood DJ; Demers MD; Dimauro J; Dixon RW; Hardman J; Kwak S; Li B; Mankovich JA; Marcotte D; Mullen KD; Ni B; Pietras M; Sadhukhan R; Sousa S; Tomlinson MJ; Wang L; Xiang T; Talanian RV
Bioorg Med Chem Lett; 2010 Jan; 20(1):330-3. PubMed ID: 19919896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
